Balaji Amines receives SEBI Warning cum Advisory Letter
Balaji Amines Ltd has received a Warning cum Advisory Letter from the Securities and Exchange Board of India (SEBI) dated September 29th, 2026, received on September 30th, 2026. The letter addresses non-submission of disclosures related to a Directorate General of Foreign Trade (DGFT) order dated August 13, 2024, and a Food and Drug Administration (FDA) letter dated January 10, 2025. SEBI observed that the company failed to disclose the DGFT order placing it on the Denied Entity List and the FDA's warning regarding 'not of standard quality' Propylene Glycol. The company stated there is no material impact on its financials or operations. SEBI has warned the company to improve compliance standards and advised immediate disclosure of the aforementioned orders and explanations for the delay.
Key Highlights
- SEBI issued a Warning cum Advisory Letter to Balaji Amines.
- Non-disclosure of DGFT order and FDA warning cited as violations.
- Company claims no material impact on financials or operations.
- SEBI advises immediate disclosure and improved compliance standards.
Price Impact
More from BALAMINES